Journal News

Finding novel drug targets
in tuberculosis

Editor’s note: Today is World Tuberculosis Day.
Jodie Johnston
By Jodie Johnston
March 24, 2020

Even 27 years since the World Health Organization declared the “white plague” a global emergency, about 1.5 million people still die from tuberculosis each year. It is estimated that around one-fourth of the world’s population is infected with this bacterial pathogen. While many cases are latent, tuberculosis can complicate other health conditions, such as HIV and diabetes, which also complicate tuberculosis treatment. Preliminary data from a small study, not yet peer reviewed, suggest that TB may also increase patients’ susceptibility to COVID-19.

The cover figure depicts the feedback inhibition of menaquinone biosynthesis by the downstream metabolite DHNA. DHNA, the last cytosolic metabolite in the menaquinone biosynthesis pathway prior to conversion to menaquinone in the membrane is shown inhibiting the reaction catalyzed by the Mtb–MenD tetramer (shown as a surface rendered structure). All compounds are shown as white sticks.

Our research team, based in New Zealand and funded by the Royal Society of New Zealand’s Marsden Fund, recently reported a novel mechanism of controlling synthesis of the essential vitamin K2 in the bacterial pathogen that causes tuberculosis. Our study was chosen as an Editors’ Pick by the Journal of Biological Chemistry.

We found that an enzyme called MenD from an early step in the process of making vitamin K2 is controlled by one of the metabolites produced at a later step, just before the vitamin K2 molecule is completed. Too much or too little vitamin K2 is toxic to the bacterium; this feedback inhibition allows the pathogen to slow down or speed up production of the vitamin.  

As far as we know, this is the first time that allosteric regulation has been reported for the menaquinone (vitamin K2) biosynthesis pathway in any domain of life.

The ability to control vitamin K2 levels is likely to help the pathogen to adapt to the changing, sometimes hostile, environment in the human host during infection. Since humans do not produce vitamin K2, the enzymes that work together to produce it in bacteria may represent targets for new antimicrobials. Our discovery of this regulation site and its structure provide a potential new target for selective drugs.

Our team includes three midcareer researchers with young families, all affiliated with the Maurice Wilkins Centre for Molecular Biodiscovery. With colleagues Ghader Bashiri and Esther Bulloch from the University of Auckland, my laboratory at the University of Canterbury plans to work to unravel more mysteries about microbial pathogens. With support from the Canterbury Medical Research Foundation and the Maurice Wilkins Centre, my lab is already tackling work on metabolic pathways in the bacteria Staphylococcus aureus, which causes a difficult-to-treat infection in healthcare settings.

Jodie Johnston
Jodie Johnston

Jodie Johnston is a senior lecturer in the School of Physical and Chemical Sciences and Biomolecular Interaction Centre at the University of Canterbury.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Your genetics influence how resilient you are to cold temperatures – new research
News

Your genetics influence how resilient you are to cold temperatures – new research

March 06, 2021

Research suggests that if you’re deficient in a certain muscle protein, your body can maintain a higher core temperature and you shiver less when exposed to cold.

Understanding cellular function to understand life
ASBMB Annual Meeting

Understanding cellular function to understand life

March 05, 2021

Geoffrey Hesketh will speak during the Molecular & Cellular Proteomics early career researcher session on proximity-dependent biotinylation at the 2021 ASBMB Annual Meeting.

Decoding organ communication systems
ASBMB Annual Meeting

Decoding organ communication systems

March 04, 2021

Ilia Droujinine will speak during the Molecular & Cellular Proteomics presentation on biological insights revealed by proteomics at the 2021 ASBMB Annual Meeting.

Branon works to break barriers in science and higher education
ASBMB Annual Meeting

Branon works to break barriers in science and higher education

March 03, 2021

Tess Branon will speak on proximity-dependent biotinylation during the Molecular & Cellular Proteomics early-career researcher session at the 2021 ASBMB Annual Meeting.

Brain Injury Awareness Month 2021
Health Observance

Brain Injury Awareness Month 2021

March 01, 2021

In the U.S., about 2.8 million people sustain a traumatic brain injury annually. Learn about recent research on TBI-related dementia, dysfunctional mitochondria and other work powering the march toward better therapies.

The evolution of proteins from mysteries to medicines
Essay

The evolution of proteins from mysteries to medicines

February 27, 2021

An essay in observance of National Protein Day.